DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,728.842 Hill Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,728.842 Hill Et Al US005728842A United States Patent (19) 11 Patent Number: 5,728.842 Hill et al. 45) Date of Patent: Mar 17, 1998 54 SUBSTITUTED IMIDAZOLYL-ALKYLTHIO 4,808,607 2/1989 Wareiing, II ............................. 514/400 ALKANOIC ACDS 5,011,851 4/1991 Meanwell ................................ 514/400 75) Inventors: David Taylor Hill, North Wales; FOREIGN PATENT DOCUMENTS Joseph Weinstock, Phoenixville; John Gerald Gleason. Downingtown, all of 0427463 5/1991 European Pat. Off. ............... 54/400 Pa. 3306646 8/1984 Germany ............................... 514/400 73 Assignee: SmithKline Beecham Corporation, 62-265270 1 1/1987 Japan ..................................... 54/400 63-141969 6/1988 Japan ..................................... 514/400 Philadelphia, Pa. WO92/O2510 2/1992 WIPO ...... ... 548/319. (21) Appl. No.: 351,443 92-004330 3/1992 WIPO .................................... 514/400 22 PCT Filed: Jun. 30, 1993 WO94/00120 1/1994 WIPO ............................... 54.8/319.1 (86 PCT No.: PCT/US93/06246 Primary Examiner-Floyd D. Higel S371 Date: Feb. 22, 1995 Attorney, Agent, or Firm-Mary E. McCarthy; Stephen A. S 102(e) Date: Feb. 22, 1995 Venetianer; Edward T. Lentz 87 PCT Pub. No.: WO94/00120 57 ABSTRACT PCT Pub. Date:Jan. 6, 1994 Angiotensin II receptor antagonists having the formula: 30 Foreign Application Priority Data Jun. 30, 1992 GB United Kingdom ................... 92.13934 (51) Int. Cl' ..................... C07D 233/60; C07D 233/84; N (CH2) th S-Rs C07D 235/02; CO7D 403/06; C07D 403/04; A61K 31/415 R-X-( R' 52 U.S. C. ...................... 548/319.1; 514/397: 514/398; N R3 514/399; 514,400; 548/321.1; 548/341.5; 548/342.1; 548/342.5 (58) Field of Search ............................ 548/319.1, 321.1. which are useful in regulating hypertension and in the 548/341.5, 342.1, 342.5; 514/397, 398, treatment of congestive heart failure, renal failure, and 399, 400 glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to (56) References Cited produce angiotensin II receptor antagonism in mammals. U.S. PATENT DOCUMENTS 4,668,794 5/1987 Wareing, I .............................. 514/400 5 Claims, No Drawings 5,728,842 1 2 acids. Specifically, the discloser includes 1-benzyl-2-n- SUBSTITUTED MDAZOLYLALKYLTHO butyl-5-chloroimidazole-4-acetic acid and 1-benzyl-2- ALKANOIC ACDS phenyl-5-chloroimidazole-4-propanoic acid. This applicationis a 371 of PCT/U.S. 93/06246 filed Jun. Furukawa, et al., U.S. Pat. No. 4355.040 discloses sub 30, 1993. 5 stituted imidazole-5-acetic acid derivatives. A compound The present invention relates to new compounds which specifically disclosed is 1-(2-chlorobenzyl)-2-n-butyl-4- are angiotensin II receptor antagonists and are useful in chloroimidazole-5-acetic acid. regulating hypertension induced or exacerbated by angio Carini et al... in European Patent Application Number tensin II, and in the treatment of congestive heart failure, 253,310 disclose certain substituted inidazoles. An inter renal failure, and glaucoma. This invention also relates to 10 mediate described in this patent is ethyl 3-1-(4-nitrobenzyl) pharmaceutical compositions containing these compounds -2-butyl-4-chloroimidazol-5-yl)propenoate. and methods for using these compounds as antagonists of Carini et al., in European Patent Application Number angiotensin II, as antihypertensive agents and as agents for 324377 disclose substituted imidazoles and processes for treating congestive heart failure, renal failure, and glau their preparation. This application also relates to pharma COa. 15 ceutical compositions containing the substituted imidazoles alone and in conjunction with other drugs, particularly in BACKGROUND OF THE INVENTION conjunction with diuretics and non-steroidal antiinflamma The class of peptide pressor hormone known as angio tory drugs. tensin is responsible for a vasopressor action that is impli cated in the etiology of hypertension in man. Inappropriate DESCRIPTION OF THE INVENTION activity of the renin-angiotensin systems appears to be a key The compounds of the present invention that are blockers element in essential hypertension, congestive heart failure of angiotensin II receptors are represented by the following and in some forms of renal disease. In addition to a direct Formula (I): action on arteries and arterioles, angiotensin II (AII), being one of the most potent endogenous vasoconstrictors known, (CH2)-R (T) exerts stimulation on the release of aldosterone from the adrenal cortex. Therefore, the renin-angiotensin system, by N e -S-Rs virtue of its participation in the control of renal sodium R4 f handling, plays an important role in cardiovascular hemeo stasis. 30 --. Interruption of the renin-angiotensin system with convert in which: ing enzyme inhibitors, such as captopril, has proved to be R" is adamantyl, phenyl, biphenyl, or naphthyl, with each clinically useful in the treatment of hypertension and con phenyl, biphenyl, or naphthyl group being unsubsti gestive heart failure (Abrams, W. B., et al., (1984), Federa tuted or substituted by one to three substituents selected tion Proc., 43. 1314). The most direct approach towards 35 from Cl, Br, F, I, C-Calkyl. nitro, A-CO'R'. inhibition of the renin-angiotensin system would block the tetrazol-5-yl, C-Calkoxy, hydroxy, SC-alkyl, action of AI at the receptor. Compelling evidence suggests SONHR, NHSOR', SOH, CONR'R''. CN, that AI also contributes to renal vasoconstriction and SOC-Calkyl, NHSOR". PO(OR), NR'R'', sodium retention that is characteristic of a number of dis NR7COH, NR7COC-Calkyl. NR7 CONOR7), orders such as heart failure, cirrhosis and complications of NRCOY, Y, or SOY; pregnancy (Hollenberg, N. K., (1984), J. Cardiovas. R’ is C-Coalkyl, Ca-Coalkenyl, Ca-Coalkenyl, Pharmacol., 6. S176). In addition, recent animal studies C-C cycloalkyl, or (CH2)osphenyl unsubstituted or suggest that inhibition of the renin-angiotensin system may substituted by one to three substituents selected from be beneficial inhalting or slowing the progression of chronic 45 C-Calkyl, nitro, Cl, Br, F, I, hydroxy. C-Calkoxy. renal failure (Anderson, S., et al., (1985), J. Clin. Invest, 76. NR'R''. COR. CN, CONR'R''. Y, tetrazol-5-yl. 612). Also, a recent patent application (South African Patent NRCOC-Calkyl, NRCOY SC-Calkyl, S.O.Y. or Application No. 87101.653) claims that AI antagonists are SOC-Calkyl; useful as agents for reducing and controlling elevated X is a single bond, S, or O; intraocular pressure, especially glaucoma, in mammals. 50 The compounds of this invention inhibit, block and R is hydrogen, Cl, Br, F, L, CHO. hydroxymethyl, antagonize the action of the hormone AI, and are therefore COOR'R' CONR'R''. NO Y. CN. NR'R''. or phenyl: useful in regulating and moderating angiotensin induced Y is CF2:1; hypertension, congestive heart failure, renal failure and A is -(CH2)-, -CH=CH-, -O(CH2)- or other disorders attributed to the actions of AI. When com 55 -S(CH2); pounds of this invention are administered to mammals, the R is H. C.-Calkyl, or -S(CH2)COR; elevated blood pressure due to ADI is reduced and other t is 0 or 1; manifestations based on AI intercession are minimized and Ris-CHR(CH2)COR” or -(CH2).R'; controlled. Compounds of this invention are also expected to R is hydrogen, CO.R. C.-Calkyl, or -(CH2).R; exhibit diuretic activity. each mindependently is 1-3; Recognition of the importance of blocking and inhibiting the actions of AI has stimulated other efforts to synthesize each n independently is 1-3: antagonists of AII. The following references have disclosed each p independently is 0-4; imidazole derivatives which are described as having AI each q independently is 0-2; blocking activity and useful as hypotensive agents. 65 each R’ independently is hydrogen or C-Calkyl: Furukawa et al., U.S. Pat. No. 4340,598 discloses R is phenyl, naphthyl 2- or 3-thienyl, 2- or 3-thiazolyl, imidazol-5-yl-acetic acids and imidazol-5-yl-propanoic triazolyl, tetrazolyl pyrazolyl pyrrolyl, oxazolyl. or 5,728.842 3 4 isoxazolyl, with each R group being unsubstituted or 4-(2-n-butyl-5-[(2-carboxyphenyl)thiomethyl-1H substituted by C-Calkyl, C-Calkoxy, Cl, Br, F, L, imidazol-5-yl)methyl-1-naphthalenecarboxylic acid. NR'R''. CONR'R''. COR”. SOH, SONHR'. OH, methyl 4-(2-n-butyl-5-[(2-carbomethoxyphenyl)-thiol NO. Y. SO2C-C alkyl. SOY. SC-Calkyl methyl-1H-imidazol-5-yl)methyl)-1-naphthalene NRCOH, NRCOY, or NRCOC-Calkyl; and carboxylate, R is phenyl. naphthyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, S-(2-n-butyl-1-(4-carboxyphenyl)methyl-4-chloro 3-, or 4-pyridyl pyrimidyl, imidazolyl, thiazolyl, 1H-imidazol-5-yl)methylthiosalicylic acid. triazolyl, tetrazolyl pyrazolyl, pyrrolyl, oxazolyl, or S-(2-n-butyl-1-(4-carboxyphenyl)methyl)-1H isoxazolyl, with each R group being unsubstituted or imidazol-5-yl)methyl-4-thiobenzoic acid, substituted by C-Calkyl, C-Calkoxy, Cl, Br, F. I. 10 NR'R''. CO.R. CONR'R', SOH SONHR'. OH, S-(2-n-butyl-1-(4-carboxyphenyl)methyl)-1H NO, Y, SQC -Calkyl, SOY, SC-C alkyl. imidazol-5-yl)methyl)-3-thiobenzoic acid, NRCOH, NRCOY, or NRCOC-Calkyl; or a phar S-(2-n-butyl-1-(4-carbomethoxyphenyl)methyl)-1H maceutically acceptable salt thereof. imidazol-5-yl)methyl)-2-thioimidazole, Preferred compounds of this invention are represented by 15 5 S-(2-n-butyl-1-(4-carboxyphenyl)methyl-4-nitro Formula (I) when: 1H-imidazol-5-yl)methylthiosalicylic acid, R" is phenyl or naphthyl, with each phenyl or naphthyl S-(2-n-butyl-1-(4-carboxyphenyl)methyl-1H group being unsubstituted or substituted by one to three imidazol-5-yl)thiosalicylic
Load more

Recommended publications
  • A2) United States Patent (10) Patent No.: US 8,940,711 B2 Olsonet Al
    US008940711B2 a2) United States Patent (10) Patent No.: US 8,940,711 B2 Olsonet al. (45) Date of Patent: Jan. 27, 2015 (54) MICRO-RNA FAMILY THAT MODULATES C1I2N 2310/321 (2013.01); C12N 2310/346 FIBROSIS AND USES THEREOF (2013.01); CI2N 2310/3515 (2013.01); C12N (71) Applicant: The Board of Regents, The University 2320/31 (2013.01); CI2N 2330/10 (2013.01) of Texas System, Austin, TX (US) USPC iececcsesseeseeesenensceesensessecsenesenscnseeee 514/444 (58) Field of Classification Search (72) Inventors: Erie N. Olson, Dallas, TX (US); Eva USPC iececcsesseeseeesenensceesensessecsenesenscnseeee 514/44A van Rooij, Utrecht (NL) See application file for complete search history. (56) References Cited (73) Assignee: The Board of Regents, The University of Texas System, Austin, TX (US) U.S. PATENT DOCUMENTS Notice: Subject to any disclaimer, the term of this 7,232,806 B2 6/2007 Tuschletal. (*) 7,674,617 B2 3/2010 Kim etal. patent is extended or adjusted under 35 2005/0059005 Al 3/2005 Tuschletal. U.S.C. 154(b) by 1 day. 2005/0222399 Al 10/2005 Bentwich 2005/0261218 Al 11/2005 Esau etal. (21) Appl. No.: 13/840,242 2006/0019286 Al 1/2006 Horvitz et al. 2006/0105360 Al 5/2006 Croceet al. Filed: Mar.15, 2013 2006/0185027 Al 8/2006 Bartel etal. (22) 2006/0247193 Al 11/2006 Taira etal. 2007/0087335 Al 4/2007 Brahmacharietal. (65) Prior Publication Data 2007/0092882 Al 4/2007 Wangetal. US 2013/0261169 Al Oct. 3, 2013 2008/0050722 Al 2/2008 Kim etal. 2008/0176766 Al 7/2008 Brown etal.
    [Show full text]
  • Deliverable 5.A Interim Report on the Study Results APPENDIX 2
    Deliverable 5.a Interim report on the study results APPENDIX 2: Algorithms used to identify study variables for service contract EMA/2011/38/CN ‐ PIOGLITAZONE November 28th 2012 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) APPENDIX 2. ALGORITHMS USED TO IDENTIFY STUDY VARIABLES Algorithms for AU Database DISEASE/CONDITION ICD-8 CODE (1977-1993) ICD-10 CODE (1994-) Diabetes type 2 250.00; 250.06; 250.07; 250.09 E11.0; E11.1; E11.9 Cancer of bladder 188 C67 Haematuria N/A R31 Haematuria, unspecified B18, K70.0–K70.3, K70.9, K71, K73, Mild hepatic impairment 571, 573.01, 573.04 K74, K76.0 Moderate to severe hepatic 070.00, 070.02, 070.04, 070.06, B15.0, B16.0, B16.2, B19.0, K70.4, impairment 070.08, 573.00, 456.00–456.09 K72, K76.6, I85 Acute myocardial infarction 410 I21-I23 Acute coronary syndrome 410, 413 I20-I24 Ischemic heart disease 410-414 I20-I25 427.09, 427.10, 427.11, 427.19, Congestive heart failure I50, I11.0, I13.0,I13.2 428.99, 782.49; Acute renal failure N/A N17 Diabetic coma N/A E10.0, E11.0, E12.0,E13.0, E14.0 Diabetic acidosis N/A E10.1, E11.1, E12.1,E13.1, E14.1 F10.1-F10.9, G31.2, G62.1, G72.1, Alcoholism 291, 303, 577.10, 571.09, 571.10 I42.6, K29.2, K86.0, Z72.1 Obesity 277.99 E65-E66 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) Algorithms for defining acute events in Denmark, ICD-10 code Event ICD-10 code I21.x, I23.x http://apps.who.int/classifications/icd10/browse/2010/en#/I21
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Guidance for the Format and Content of the Protocol of Non-Interventional
    PASS information Title Metformin use in renal impairment Protocol version identifier Version 2 Date of last version of 30 October 2013 protocol EU PAS register number Study not registered Active substance A10BA02 metformin Medicinal product Metformin Product reference N/A Procedure number N/A Marketing authorisation 1A Farma, Actavis, Aurobindo, Biochemie, Bluefish, holder(s) Hexal, Mylan, Orifarm, Pfizer, Sandoz, Stada, Teva Joint PASS No Research question and To assess the use and safety of metformin in patients objectives with and without renal insufficiency in current clinical practice in at least two EU Member States. Country(-ies) of study Denmark, United Kingdom Author Christian Fynbo Christiansen, MD, PhD Page 1/214 Marketing authorisation holder(s) Marketing authorisation N/A holder(s) MAH contact person N/A Page 2/214 1. Table of Contents PASS information .......................................................................................................... 1 Marketing authorisation holder(s) .................................................................................... 2 1. Table of Contents ...................................................................................................... 3 2. List of abbreviations ................................................................................................... 4 3. Responsible parties .................................................................................................... 5 4. Abstract ..................................................................................................................
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://edhub.ama-assn.org/ on 09/24/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • |||||IIIUSOO57673 10A United States Patent (19) 11 Patent Number: 5,767,310 Bagley Et Al
    |||||IIIUSOO57673 10A United States Patent (19) 11 Patent Number: 5,767,310 Bagley et al. 45 Date of Patent: Jun. 16, 1998 (54) PHENOXYPHENYLACETIC ACD 2259 540 3/993 United Kingdom. DERVATIVES WO 92 O0952 1/992 WIPO WO 92 12991 6/992 WIPO (75) Inventors: Scott W. Bagley, Groten. Conn.; WO 92/15321 9/1992 WIPO Theodore P. Broten, Ambler, Pa.; WO 92/2O706 11|1992 WIPO WO 93 08799 5/1993 WIPO : Prasun K. Chakravarty. Edison, N.J.; WO 93 O144 5/1993 WIPO Daljit S. Dhanoa, La Jolla, Calif.; WO 93 13052 7/1993 WIPO Kenneth J. Fitch, Cranford, N.J.; WO 93 13069 7/1993 WIPO William J. Greenlee, Teaneck, N.J.; WO 93 23.404 11/1993 WIPO Nancy Jo Kevin, Clifton, N.J.; Douglas WO 94 14796 12/1993 WIPO J. Pettibone. Chalfont, Pa.; Ralph A. WO 94 O2474 2/1994 WIPO Rivero, North Wales, Pa.; James R. WO 94. 14434 7/1994 WIPO. Tata, Westfield; Thomas F. Walsh. Watchung, both of N.J.; David L. OTHER PUBLICATIONS Williams, Jr., Telford, Pa, "Endothelin: A New Challenge", Doherty, A.M., J. Med. Chem. vol. 35. No. 9, (1992), pp. 1493-1508. 73) Assignee: Merck & Co., Inc.. Rahway, N.J. "Studies on the Chemical Constituents of Rutaceous 21 Appl. No.: 507,492 Plants. ''). Development of a Versatile Method for the Synthesis of Antitumor-Active Benzoic phenanthridine (22 PCT Filled: Mar 17, 1994 Alkaloids. (2)' Preparation of 2-Aryl-1-tetralone Deriva 86) PCT No.: PCT/US94/02871 tives', Ishii, H. et al. Chem. Pharm. Bulletin, vol.
    [Show full text]
  • Table of Antihypertensive Drugs
    Chapter 14 Table of Antihypertensive Drugs F. GROSS and J. B. LUTH The following tables give information about the most important drugs used today in the treatment of high blood pressure. These lists do not in any way aim for completeness, in particular with respect to brand names, which are much more numerous for several of the mentioned products. The usual forms of adminis­ tration and average dosages are included, but various other schemes are also recommended for some drugs in some countries. What is said for the single entities with respect to completeness holds true even more for the fixed combinations, of which only a fraction of those marketed in a number or'countries has been included. Some examples of the combinations that make sense to the authors have been mentioned; many have been omitted; however, deletion does not mean in all cases - but it does in some - that the combi­ nation is considered useless. If a barbiturate is added to reserpine and a diuretic, it is difficult to ascribe to the new combination an improved effect on the high blood pressure. Quite a few more examples could be given, where the addition of a further ingredient to the basic combination of reserpine and a diuretic is nothing but the mixing in of a special flavor, and not of an antihypertensive component. Some of the readers may also feel that too many drugs and combinations have been listed, and they may never have heard the names of quite a few of them. Despite the incompleteness of the list, it gives an impression of the huge variety of pre­ parations, which will further increase with the growing number of /J-adrenergic blockers and their combinations with other drugs.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,565,485 Bagley Et Al
    US005565485A United States Patent (19) 11 Patent Number: 5,565,485 Bagley et al. (45) Date of Patent: Oct. 15, 1996 (54) BLPHENYL COMPOUNDS USEFUL OR "BQ123, An ET(A) Receptor Antagonist, Attenuates ENDOTHELIN ANTAGONSTS Hypoxic Pulmonary-Hypertension in Rats' Bonvallet, S.T., et al. American Journal of Physiology, vol. 266, No. 4, (Apr. (75) Inventors: Scott W. Bagley, Groton, Conn.; 1994), pp. H1327-1331. Theodore P. Broten, Ambler, Pa.; "Endothelin-A Receptor Antagonist Prevents Acute Prasun K. Chakravarty, Edison, N.J.; Hypoxia-Induced Pulmonary-Hypertension in the Rat' Daljit S. Dhanoa, Secaucus, N.J.; Oparil, S., et al. American Journal of Physiology-Lung Kenneth J. Fitch, Scotch Plains, N.J.; Cellular and Molecular Physiology, vol. 12, No. 1, (Jan. William J. Greenlee, Teaneck, N.J.; Nancy J. Kevin, Clifton, N.J.; Douglas 1995), pp. L95-L100. J. Pettibone, Chalfont, Pa.; Ralph A. "Protection from Pulmonary Hypertension with an Orally Rivero, Tinton Falls, N.J.; Thomas F. Active Endothelin Receptor Antagonist in Hypoxic Rats' Walsh, Westfield, N.J.; David L. American Journal of Physiology-Heart and Circulatory Williams, Jr., Telford, Pa.; Richard B. Physiology, vol. 37, No. 2, (Feb. 1995), pp. H828-H835. Toupence, Cranford, N.J.; Jay M. "Endothelial Dysfunction and Remodeling of the Pulmonary Matthews, Fords, N.J. Ciculation in Chronic Hypoxic Pulmonary-Hypertension' Dinhxuan, A. T., et al. ACP-Applied Cardiopulmonary 73 Assignee: Merck & Co., Inc., Rahway, N.J. Pathophysiology, vol. 5, No. 2, (1994), pp. 93-99. "Cyclosporine-induced Elevation in Circulating Endothe 21 Appl. No.: 294,232 lin-1 in Patients with Solid-Organ Transplants' Grieff, M., et al.
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Blood Pressure-Lowering Efficacy of Reserpine for Primary Hypertension (Review)
    Cochrane Database of Systematic Reviews Blood pressure-lowering efficacy of reserpine for primary hypertension (Review) Shamon SD, Perez MI Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD007655. DOI: 10.1002/14651858.CD007655.pub3. www.cochranelibrary.com Blood pressure-lowering efficacy of reserpine for primary hypertension (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 Figure1. ..................................... 6 Figure2. ..................................... 8 Figure3. ..................................... 10 Figure4. ..................................... 11 Figure5. ..................................... 12 Figure6. ..................................... 13 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 18 DATAANDANALYSES. 26 Analysis 1.1. Comparison 1 Reserpine versus placebo, Outcome 1 Weighted mean change in systolic blood pressure. 27 Analysis 1.2. Comparison 1 Reserpine versus placebo, Outcome 2 Weighted mean
    [Show full text]